Celcuity (CELC) investor relations material

Regulatory and clinical development updates

• Positive phase 3 data in breast cancer and NDA acceptance with a PDUFA date set for July 17, 2024, with launch expected soon after approval.

• Full data for both PIK3CA wild-type and mutant cohorts from the VIKTORIA-1 study will be available to physicians at launch.

• RTOR program review is not expected to accelerate approval beyond the PDUFA date based on historical precedent.

• Mutant phase 3 readout is expected late Q1 or Q2, with enrollment targets met and event rates monitored quarterly.

• Phase 3 success defined as a statistically significant improvement in median PFS over alpelisib, with a 10-month median PFS considered both statistically and clinically meaningful.

Commercial readiness and strategy

• Chief Commercial Officer hired in Q1 2024; senior commercial leadership and most commercial functions are in place, with only field sales reps left to hire.

• Company-wide transition to commercial stage includes upgrades to IT, safety, HR, and administrative systems.

• Confident in executing a go-it-alone launch but open to strategic options; focus remains on maximizing drug penetration.

• Cash position of $450 million at end of Q3, with access to up to $500 million in term loans, providing financial flexibility.

Scientific and clinical insights

• Gedatolisib offers comprehensive inhibition of the PAM pathway, addressing redundancy mechanisms and showing unprecedented efficacy in PIK3CA wild-type breast cancer.

• Data show a 76% reduction in risk of progression or death, with a fivefold improvement in PFS over endocrine therapy.

• Tolerability profile is favorable, with stomatitis occurring early and resolving quickly, and no degradation in patient sense of well-being over time.

• Infused drugs are well-accepted in oncology practices, and compliance is higher compared to oral therapies.